Background: Relative to the oral contraceptive pill, uptake of long-acting reversible contraceptive methods (LARCs) in Australia continues to be lower than might be suggested by the evidence on their clinical and economic benefits.
INTRODUCTION
Evidence shows that increasing the use of long-acting reversible contraceptive products (LARCs) has the potential to reduce unintended pregnancy and abortion rates. 1 LARCs are contraceptives that once initiated, function for as long as they contain active ingredients or Australian College of General Practitioners (RACGP), which included a framework for action to increase the use of LARCs in Australia. 2 More recently, the Australian Healthcare and Hospitals Association (AHHA) released a consensus statement, endorsed by the Royal Australian New Zealand College of Obstetricians and Gynaecologists calling for increasing access to LARCs for Australian women. 3 Although a wide range of LARCs is available in Australia, their uptake has been slow. 4, 5 Between 2004 and 2010, overall contraceptive use among women was reported to be 69%, with intrauterine or implantable LARCs comprising 6.8%. 6 The relative lack of uptake of LARCs has variously been explained by the attitudes and habits of doctors and women, the upfront costs of LARCs, and the lack of suitable training for LARC insertion. [7] [8] [9] [10] In Australia, it is likely that much can be explained by the popularity of the combined oral contraceptive pill (OC), 11 which is well-established and subsidised by the Australian government via the Pharmaceutical Benefits Scheme (PBS). 4, 5, 12 While some LARCs are also funded via the PBS (Mirena® and Implanon®), improving the uptake and use of LARCs more generally is a challenge given barriers to access 5, 7 and the broad experience base with OCs.
One means of addressing this challenge is to evaluate the costeffectiveness of LARCs relative to other contraceptives. 5 Published cost-effectiveness studies have reported that LARCs are costeffective and may be cost-saving in the long term. [13] [14] [15] However, there are no Australian studies of the cost-effectiveness of LARCs, making it tempting to use international published studies. While the clinical outcomes (eg avoidance of unintended pregnancies) from overseas studies are likely to be generalisable to local settings, costs may be less so, making it important to examine the quality of that evidence. The aim of this study was to undertake a critical appraisal of published economic evaluations of LARCs, with a view to discussing their generalisability to Australia.
MATERIALS AND METHODS

Study selection
A search of the literature was conducted to identify studies of economic evaluations of LARCs. The search was conducted in Medline and Embase via the Ovid interface in March 2017, and without specifying date limits. The search terms and study exclusion criteria are provided in Figure 1 . Additional relevant papers were sourced using an ancestry search of the references of included papers. Retrieved citations were initially reviewed by MH and RL. Discordance was discussed and full papers retrieved for review. RL and ML conducted the review of full-text papers in consultation with the other authors.
Quality assessment
The quality of the studies was evaluated using the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS)
checklist, a standard set of criteria for the evaluation of published economic evaluations. 16 Each study was scored one point for each criterion that was fully met, one/two points if a criterion was 'somewhat' met, and zero for criteria that were either not met ('no') or not applicable. Each paper's score was estimated by summing the criteria scores and dividing the total by the number of applicable fields (excluding those criteria which did not apply to a study) and multiplying by 100. For each quality criterion, the proportion of papers that fully or partially met each criterion (out of all to which the criterion applied) is reported in Table 1 ; the individual quality score for each paper is reported in Table 2 .
Data reporting
In some instances, the costs and clinical outcomes reported by papers have been re-expressed for comparability across studies.
Where possible, costs were expressed as the average cost per woman per year (total costs divided by the number of women in the relevant cohort). If a study reported only total costs, the incremental cost was estimated based on the difference in the reported costs for each treatment group of interest. The year in which prices were reported (or the year of publication if the latter was not reported) was converted to 2017 prices in the original currency using online inflation calculators for the UK, 17 USA 18 and the European Union. 19 For comparability, once all costs were converted to 2017 prices, they were converted to Australian dollars (AUD) using an online currency converter. To enable cross-study comparisons, where possible, outcomes were converted to the number of unintended pregnancies per 1000 women per year. Where studies reported the incremental cost-effectiveness ratios (ICER) -calculated as the difference in costs of the intervention and its comparator expressed as a ratio to the difference in the outcomes of the intervention and its comparator 24 -this was extracted, and was typically expressed as the cost per unintended pregnancy avoided. If the ICER was not explicitly reported, it was generated by multiplying the difference in costs between interventions by 1000 and dividing it by the number of pregnancies avoided per 1000 women. Following standard health economic principles, 24 an intervention was reported as dominant if it resulted in more outcomes (eg pregnancies avoided) and lower costs than its comparator.
RESULTS
Studies identified
A total of 1009 citations were screened from which 20 papers were suitable for inclusion. Of these, 11 reported research un- LARCs (implants and IUDs). Because these studies were in specific sub-groups of women and the comparison formed was between the timing of LARC insertion, they are presented separately. The maximum time horizon over which costs and outcomes were investigated varied between one and 15 years (Table 2) .
Costs
All studies included intervention costs, including contraceptive costs, medical consultations, contraceptive insertion and removal where relevant. Two studies, conducted from a societal perspective, also included productivity costs. 38, 39 One study excluded the costs of unintended pregnancy, on the grounds its effects were already captured in the outcome measure (unintended pregnancy). 36 Four studies included the costs of side effects (e.g. venous thromboembolic disease) or the reduced costs (benefit) associated with a lower risk of serious menstrual disorders.
14,25,31,32
Outcomes
Of the 20 studies, 12 reported health outcomes in terms of the impact on pregnancies, typically the number of unintended pregnancies, which allowed estimation of the number of pregnancies avoided. 13, 21, 23, 26, 28, [30] [31] [32] [33] 35, 36, 39 Four studies reported health outcomes as an aggregated measure of cost-benefit from which it was not possible to calculate average health effects. 25, 29, 34, 38 In one of these studies, Trussell et al. (1995) , the number of pregnancies avoided was reported graphically only, so it was not possible to extract the outcomes data. 32 In two other studies, effectiveness outcomes were reported as couple years of protection, making The terms "LARC or long-acting reversible contracept*" or "long-term reversible contracept*" were combined with the specific generic names for each LARC type (intrauterine device OR levonorgestrel intrauterine system OR depot medroxyprogresterone acetate OR etonogestrel subdermal implant) and the following MESH (Medical Subject Headings) terms: economic evaluation or cost-effectiveness analysis or cost-benefit analysis or cost-utility analysis or costminimization analysis or costs and cost analysis or economics. The following terms were searched as text words and combined with the contraceptive terms to maximise the retrieval of relevant studies: economic evaluation or cost effective* or cost-benefit or cost utilit*or cost-minimization or cost-minimisation or cost* or economic*. One of these six elements is missing.
Two or more of these elements are missing.
0.64
Background and objectives Broader context for the study and the research question and its relevance for health policy or practice decisions are made clear.
The relevance of the study for decision makers is not established in the introduction, but research question and context are.
The study question is not adequately presented, or both broader context and relevance are missing.
1.00
Target population and sub-groups Characteristics of the base case population described and justified.
Some characteristics described but missing important information.
No consideration of a target population.
0.71
Setting and location Relevant aspects of system in which decision needs to be made are described.
Location of study is acknowledged but it
is not clear what setting decision needs to be made in.
Setting is not considered or is not made clear.
0.89
Study perspective Perspective of the study is explicit and the costs being evaluated relate to this.
Perspective is considered but the study does not clearly relate costs to it.
Perspective is not made explicit at any point.
0.84
Comparators Interventions being compared are clearly described (including model types of LARCs) and there is some justification for their inclusion.
There is a lack of justification for comparators or a lack of detail in the description of them (eg IUS is used rather than LNG-IUS20 or Mirena).
There is a lack of justification for choices and a lack of necessary detail.
0.74
Time horizon Time-horizon over which costs and consequences are being evaluated is reported and justified.
Time-horizon is given and consistent but there is no justification for it.
Time-horizon is inconsistent or unclear.
0.53
Discount rate Discount rate used for costs and outcomes is reported and justified.
Discount rate is applied appropriately, rate is not justified.
Discounting is not applied or is applied inconsistently/not clearly.
0.50
Choice of outcomes Outcomes are used as the measure of benefit in the evaluation and these are described.
Health outcomes are discussed but not as the primary object of the study.
Health outcomes are not included as part of the study.
0.79
Measurement of effectiveness Design of a single effectiveness study or the methods of identification and synthesis of clinical effectiveness data is made clear, and justification is
given for these sources of data.
There is either a lack of justification for data used, or a lack of explanation as to finding and selecting sources.
Identification of sources and justification for their use are both omitted, or data are synthesised without a description of how this is done.
0.63
Measurement and valuation of preference-based outcomes Population and methods used to elicit preferences for outcomes are clearly described and results are clearly presented. One minor set of price information is not displayed.
Crucial element of price information or resource use is not included, costs are applied inconsistently or sources for resource use or prices are not provided.
0.71
Currency, price date and conversion Price date information is provided, and sufficient currency conversion information is provided (if applicable).
Either conversions or price dates (but not both) have been adequately considered.
Neither price dates nor conversions have been adequately considered.
0.50
Choice of model The model is well described and clear.
Most of the model is well described, but some elements are unclear.
The model is either inadequately described or has an unclear structure.
0.60
Assumptions All structural or other assumptions underpinning the model are described.
All major assumptions are described.
Some major assumptions are not sufficiently described.
0.86
Analytic methods All analytical methods supporting the evaluation are described.
One analytic method is omitted.
More than one method is omitted.
0.82
Study parameters All major sets of parameters are displayed.
One significant set of parameters is not displayed.
Multiple sets of parameters are not displayed.
0.74
Incremental costs and outcomes Mean values for main cost/outcome categories as well as mean differences and incremental costeffectiveness ratios are reported.
Mean differences and incremental ratios are missing for some values or there are some errors in the data.
Mean differences and incremental ratios have not been used.
0.61
Characterising uncertainty There is a comprehensive handling of uncertainty, including sensitivity analysis on varying costs, discontinuation and failure estimates.
At most one of these elements is not altered, but otherwise there is a good characterisation of uncertainty. More than one of these elements is not altered in the uncertainty analysis.
0.50
Characterising heterogeneity Some subgroup analysis was performed.
There is an understanding of possible effects of heterogeneity but no analysis of them.
There is no acknowledgement of heterogeneity.
0.21
Study findings, limitations, generalisability and current knowledge Key study findings are summarised and conclusions generated from these. Limitations and generalisability of the findings, as well as how they fit with current knowledge are discussed.
At most the link to current knowledge or the discussion of generalisability is missing.
Either both of these elements are missing or any other element is missing.
0.47
Source of funding Funding is fully declared.
Funding is partially or unclearly declared.
Funding is not acknowledged at all.
0.84
Conflicts of interest Potential for conflict of interest is clearly disclosed.
There is an appreciation of potential influence or bias but no explicit disclosure of conflicts of interest.
This issue is not considered.
0.39
CHEERS, Consolidated Health Economic Evaluation Reporting Standards; LARC, long-acting reversible contraceptive; LNG-IUS, levonorgestrel-releasing intrauterine system 
IUD (data inputs from Mirena ™ and
Copper-T IUD)
Women, post-partum 3% applied to outcomes only. 2014 USD (P/C)OC, (progesterone/combined) oral contraceptive; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; CYP, couple year of protection; DMPA, depot medroxyprogesterone acetate; GBP, pounds (UK); ICER, incremental cost-effectiveness ratio; IPI, immediate postpartum implant; IUC, intrauterine catheter; IUD, intrauterine device; LARC, long-acting reversible contraception; LNG-IUS, levonorgestrel intrauterine system; NHS, National Health Service; SARC, short-acting reversible contraception; USD, Dollars (US). A comprehensive sensitivity analysis investigated the effects of uncertainty for all input parameters, and uncertainty related to the structure of the model and assumptions; a partial sensitivity analysis considered only some input parameters or variations in model structure. Immediate post-partum insertion (ten minutes post-placental expulsion) dominates routine insertion (6-8 weeks) post-partum of IUD. Results were most sensitive to the costs of pregnancy
None
comparisons between studies more difficult. 22, 37 The remaining two studies reported outcomes on the basis of quality-adjusted life years (QALYs) gained, a metric which combines the effect of contraception on women's quality of life with overall survival.
14,39
Study quality
The overall quality of the studies varied, with CHEERs checklist scores ranging between 33/100 29 and 91.5/100 23 ( Table 2 ). The average score was 62/100, indicating generally low quality. This may be partly due to insufficient availability of data on contraceptive failure and discontinuation rates; nine of the studies drew almost all their clinical data from two reviews, both of which used the same data from the American National Survey of Family Growth, collected between 10 and 20 years ago. 40, 41 All papers with scores below 40 scored a 'no' on the criterion requiring the inclusion of sufficient clinical effectiveness data. 26, 29, 35 In addition, a number of the studies were deficient in terms of some of the nine did not include price date information 22, 25, [27] [28] [29] 32, 34, 35, 38 and only seven comprehensively handled uncertainty. 13, 23, 28, 31, 35, 36, 38 In addition, two studies 22, 37 did not separately report the costs and effectiveness of each intervention, but only reported the ratio of the cost and effectiveness within each intervention.
Assessment of cost-effectiveness
Oral contraception (usually the OC) was generally chosen as the main comparator. Where multiple SARCs were included, pairwise comparisons were extracted for OC relative to LARCs due to its ) found that Norplant® was both more costly and more effective than OC, but only over a one-year time period. 21 Ortmeier et al. (1994) found that the injectable Depo-Provera was cost-saving relative to OC, but that Norplant was more costly than OC. 29 The results in which LARCs did not dominate OC come from three of the oldest five studies. Overall, the evidence suggests that LARCs are cost-effective compared to OC once they are used beyond one to two years.
The results of the relative cost-effectiveness of different LARC methods were more varied (see Table 4 ); effectiveness and cost differences between interventions were smaller and were less robust under sensitivity analyses. Generally, IUDs were less costly and less effective than IUS and implants, but probably showed LARCs to be dominant (ie less costly and more effective). 
Generalisability of findings
The overall finding that LARCs dominate SARCs with respect to the prevention of pregnancy can probably be generalised to settings with similar costs and effectiveness as those included in the studies in this review. While it is reasonable to assume that the effectiveness of LARCs in terms of reductions in unintended pregnancies will be similar in Australia to that reported in the studies included in this review, this is tempered to some extent by the variation in the age ranges covered by those studies -ranging from an age of 13 years 27 and up to 50 years of age. Australia, and other countries beyond those in which the studies were conducted, it is necessary to understand the potential for country-specific differences in the organisation and funding of healthcare services, including the availability of different LARC methods, to influence the local cost-effectiveness of these technologies.
Limitations of the studies reviewed
An important limitation of all studies was the quality of the effectiveness data used. Many studies relied on the same one or two papers for their methods and inputs, many of which are now out of date. 30, 32, 36, 38, 39, 43 This will affect whether the rates of 'typical use' reflect current practice, both in terms of utilisation and resulting failure rates. In addition, the contraception discontinuation rates varied significantly between studies. 
Many
Limitations of the methods used in the evaluation of the studies
Although a well-regarded reporting checklist (the CHEERS checklist) was used to judge the quality of the studies, some degree of subjectivity is always involved in applying such methods. Although not easy to overcome, a recognised limitation of such checklists is that all criteria are weighted equally. Thus, it is important to not overstate the ability of the scores to differentiate between the quality of studies.
Limitations must also be acknowledged in terms of the calculations undertaken to enhance study comparability. Prices were converted to 2017 values before the process of currency conversion was undertaken. Reversing the order of these conversions produces different values; while this would impact on the absolute magnitude of the costs, it would not alter the relative ranking of costs for LARCs versus SARCs within or across studies. Discount rates were not adjusted in the calculations. This means that the results reported by studies using different discount rates or no rates are being compared. Finally, there may be rounding errors in our analysis as the original data were not available for use.
Future directions for exploring the value of LARCs
While our review supports the cost-effectiveness of LARCs com- Cost-benefit analyses, using willingness to pay (WTP) to value the effects of contraceptives, are one way to expand the scope of the costs and benefits considered. 45 Such an approach would enable the comparison of alternative contraceptive methods (eg LARC vs SARC or one type of LARC vs another) and also offers advantages by capturing benefits beyond health, which seem to be particularly relevant to contraception, but is as yet largely unexplored in this literature.
CONCLUSION
Although many of the studies we reviewed had methodological limitations, it is likely that, from a policy perspective, LARCs are cost-effective. The low uptake of LARCs in Australia warrants further exploration in terms of the value women place on the benefits (both health and beyond health) of the alternative contraceptive products available to them. Developing local evidence of cost-effectiveness is one means of informing the allocation of healthcare resources to improve health outcomes.
